Neonatal magnesium sulphate for neuroprotection: A systematic review and meta-analysis.
Emily Shepherd, Tasneem Karim, Sarah McIntyre and 5 others
PMID 38468452WHAT IT FOUND
Magnesium sulphate may reduce neonatal death in asphyxiated babies, but the advantage vanishes when only the two well-conducted trials are examined.
No trial showed improved long-term brain development.
Key findings
01Magnesium sulphate versus placebo or no treatment was associated with reduced neonatal death across 13 RCTs (1033 infants), but this advantage disappeared in a sensitivity analysis restricted to the two trials at low risk of bias (102 infants).
02No clear difference was found in death or neurodevelopmental disability at 12 months (one RCT, 41 infants), and no added reduction in neonatal death was seen when magnesium sulphate was given on top of therapeutic hypothermia (three RCTs, 269 infants).
03Several short-term outcomes improved with magnesium sulphate versus placebo, including fewer seizures, fewer CT abnormalities at day 14, fewer neurological abnormalities at discharge, and less need for oxygen, but no clear adverse effects were identified.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Only four of the 25 RCTs were at low risk of bias overall, and the sensitivity analysis that excluded the rest included just two small trials (102 infants). Seventy-nine percent of the included studies were conducted in low- and middle-income countries, where the evidence for therapeutic hypothermia is uncertain, so the results may not apply to settings where hypothermia is routine. Long-term neurodevelopment was reported in only five of the 25 RCTs, at varying time points (6 to 24 months), making it impossible to draw firm conclusions about brain outcomes. The studies varied widely in how they defined asphyxia, the severity of HIE included, the magnesium sulphate dose and timing, and the outcomes they measured.
Declared interests
The authors declared no conflicts of interest. The work was funded by the National Health and Medical Research Council, Australia.
The easy way to misread this
Do not read the reduced neonatal death as proof that magnesium sulphate works. The advantage disappeared when only the two well-conducted trials were examined (102 infants), and 79% of the included studies were in settings where the evidence for therapeutic hypothermia is uncertain.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →